Comparative Pharmacology
Head-to-head clinical analysis: CLINIMIX E 5 20 SULFITE FREE W ELECT IN 20 DEXTROSE W CALCIUM IN PLASTIC CONTAINER versus TRAVASOL 2 75 SULFITE FREE W ELECTROLYTES IN DEXTROSE 25 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINIMIX E 5 20 SULFITE FREE W ELECT IN 20 DEXTROSE W CALCIUM IN PLASTIC CONTAINER versus TRAVASOL 2 75 SULFITE FREE W ELECTROLYTES IN DEXTROSE 25 IN PLASTIC CONTAINER.
CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER vs TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Parenteral nutrition providing essential amino acids, electrolytes, and dextrose for caloric support and protein synthesis.
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% is a parenteral nutrition solution providing calories (dextrose), amino acids (for protein synthesis), and electrolytes for maintenance of acid-base balance and cellular function. Dextrose is metabolized to glucose, which undergoes glycolysis and oxidative phosphorylation. Amino acids are used for protein synthesis and as an energy source. Electrolytes correct or prevent deficiencies.
Intravenous. Adult: 2 L/day (providing 100 g protein and 400 g dextrose) or as per metabolic needs. Rate: 100 mL/hr initially, adjusted based on tolerance and glucose monitoring.
Intravenous infusion only. Adult dose determined by nutritional requirements and metabolic tolerance. Typical dose: 500-2000 mL/day infused continuously or intermittently, with dextrose dosage not exceeding 0.5 g/kg/h. Final concentration of dextrose and amino acids must be monitored.
None Documented
None Documented
Amino acids: 0.5-2 hours (rapid clearance dependent on metabolic demand). Glucose: ~2-4 hours in euglycemic states. No single terminal half-life due to mixture.
Dextrose: rapid, minutes (insulin dependent); amino acids: 20-30 min for free pool turnover; electrolytes: distribution half-life 2-4 hours, elimination depends on renal function. Clinical: continuous infusion maintains steady state.
Components are primarily metabolized; nitrogen waste excreted renally as urea (85-90%), with minimal biliary/fecal elimination (<5%). Electrolytes and dextrose are fully metabolized or excreted renally.
Primarily renal (glomerular filtration). Dextrose is completely metabolized; electrolytes (sodium, chloride, potassium, calcium, magnesium, acetate) are excreted via kidneys. Acetate is metabolized to bicarbonate. No significant biliary/fecal elimination.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution